Skip to main content

Table 2 Transplant relevant data

From: BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibition

Variable

All patients (n = 352)

Deceased <65y (n = 198)

Deceased >65y (n = 71)

Living AB0c(n = 61)

living AB0i(n = 22)

ANOVA or chi2p-value

No BK (n = 304)

BK (n = 48)

T-test or chi2p-value

Donor age (years)

54.5 ± 14.0

48.3 ± 13.0

70.9 ± 5.7

55.9 ± 8.6

52.4 ± 8.4

0.0002

54.1 ± 13.8

56.8 ± 15.1

n.s.

Donor sex (male / female)

166 / 186

95 / 103

33 / 38

29 / 32

9 / 13

n.s.

146 / 158

20 / 28

n.s.

Donor BMI (kg/m 2 )

26.5 ± 4.5

26.6 ± 4.5

27.1 ± 5.5

26.2 ± 3.4

25.1 ± 3.2

n.s.

26.4 ± 4.3

27.4 ± 5.3

n.s.

Donor creatinine (mg/dl)

0.98 ± 0.62

1.03 ± 0.75

1.01 ± 0.53

0.81 ± 0.16

0.85 ± 0.12

n.s.

0.99 ± 0.65

0.91 ± 0.34

n.s.

Donor creatinine >1.5 mg/dl (n/%)

37 / 10.5

26 / 13.1

11 / 15.5

0 / 0

0 / 0

0.004

33 / 10.9

4 / 8.3

n.s.

Donor diuresis (ml/h)

156 ± 99

177 ± 106

158 ± 101

92 ± 24

108 ± 33

0.0005

158 ± 101

144 ± 82

n.s.

Cold ischemic time (h)

10.3 ± 5.8

13.3 ± 4.1

11.2 ± 3.9

2.2 ± 1.2

2.6 ± 1.1

0.0006

10.2 ± 5.8

10.7 ± 5.8

n.s.

HLA mismatch (n)

2.9 ± 1.7

2.4 ± 1.6

3.9 ± 1.2

3.4 ± 1.6

3.4 ± 1.3

0.0001

2.9 ± 1.6

2.9 ± 1.7

n.s.

Number of 0 mismatches (n/%)

41 / 11.6

38 / 19.2

1 / 1.4

2 / 3.3

0 / 0

0.0004

34 / 11.2

7 / 14.6

n.s.

Tacrolimus (n/%)

280 / 79.5

163 / 82.3

45 / 63.4

50 / 82.0

22 / 100

0.0005

242 / 79.6

37 / 77.1

n.s.

Cyclosporine (n/%)

72 / 20.5

35 / 17.7

26 / 36.6

11 / 18.0

0 / 0

0.0005

62 / 20.4

11 / 22.9

n.s.

ATG-induction (n/%)

65 / 18.5

48 / 24.2

8 / 11.3

7 / 11.5

2 / 9.1

0.018

57 / 18.7

8 / 16.7

n.s.

IL2-Induction (n/%)

280 / 79.5

145 / 73.3

61 / 85.9

54 / 88.5

20 / 90.9

0.010

241 / 79.3

39 / 81.2

n.s.

No induction (n/%)

7 / 2.0

5 / 2.5

2 / 2.8

0 / 0

0 / 0

n.s.

6 / 2.0

1 / 2.1

n.s.

Early steroid withdrawal (n/%)

46 / 13.1

30 / 15.1

12 / 16.9

4 / 6.6

0 / 0

n.s.

43 / 14.1

3 / 6.2

n.s.

PRAs (n/%)

45 / 12.8

34 / 17.2

6 / 8.4

4 / 6.6

1 / 4.5

0.044

36 / 11.8

9 / 18.7

n.s.

CMV risk profile (D - R - , D - R + , D + R + , D + R - )%

18/26/35/21

18/32/30/20

10/25/44/21

21/15/38/26

27/5/41/27

0.035

18/23/36/23

15/44/31/10

0.014

Study participant (n/%)

126 / 35.8

82 / 41.4

22 / 31.0

22 / 36.1

0 / 0

0.001

117 / 38.5

9 / 18.7

0.009

Primary function (n/%)

251 / 71.3

128 / 64.6

47 / 66.2

55 / 90.2

21 / 95.5

0.0006

216 / 71.1

35 / 72.9

n.s.

Creatinine at discharge (mg/dl)

2.04 ± 0.94

2.08 ± 0.98

2.40 ± 1.00

1.67 ± 0.69

1.56 ± 0.50

0.0001

2.00 ± 0.86

2.28 ± 1.33

0.057

eGFR at discharge (ml/min)

35.5 ± 14.7

35.1 ± 14.8

27.3 ± 9.8

43.1 ± 14.6

42.8 ± 13.1

0.0001

35.9 ± 14.7

33.3 ± 14.4

n.s.

  1. BMI = body mass index, GFR = glomerular filtration rate, ATG = antithymocyte globulin, IL2 = interleukin 2, PRA = panel reactive antibodies, CMV = cytomegalovirus.
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us